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ABSTRACT 
A simple, sensitive and reproducible reverse-phase high performance liquid chromatographic (RP-
HPLC) method has been developed for the quantitative estimation of Atorvastatin calcium in the 
pharmaceutical formulations. Chromatographic separation was achieved on a 250 × 4.6 mm, 5µ, 
Waters symmetry column. The flow rate was 1ml/min and eluent was monitored by absorbance at 246 
nm using a mixture of Methanol and Acetonitrile (pH 3.0±0.01) in the ratio of 25:75 (v/v). The 
retention times of Atorvastatin calcium was found to be 5.5 min. Calibration plots were linear in the 
concentration range of 5-25 µg/ml for Atorvastatin calcium. The total run time is 12 min. The 
proposed method was validated by testing its linearity, recovery, specificity, system suitability, 
precision (Interday, intraday, analyst and instrument precision), robustness and LOD/LOQ values and 
it was successfully employed for the determination of Atorvastatin calcium in pharmaceutical tablet 
formulations. 
Keywords: HPLC, Acetonitrile, Atorvastatin calcium, Validation. 
1.  Introduction: 
Atorvastatin calcium (ATOR) (Fig. 1) is the 
calcium salt (2:1) trihydrate of [R-(R*,R*)]-2-
(4-fluorophenyl)-b,d-dihydroxy-5-(1-methyl 
ethyl)- 3- phenyl4 [ (phenylamino) carbonyl] lH 
pyrrole- heptanoic acid. It is an inhibitor of 3-
hydroxy- 3- methyl glutaryl- coenzyme A 
(HMGCoA) reductase. Atorvastatin is the most 
efficacious of the currently available HMG-CoA 
reductase inhibitors in terms of lowering plasma 
cholesterol levels by suppressing the hepatic 
production of very low density lipoprotein 
(VLDL) and low density lipoprotein (LDL) 
cholesterol 1. 
A novel formulation Atorvastatin calcium 
commercially available, benefits for 
antihyperlipidemic action. This provides 
powerful efficacy for day long control of BP and 
has proven evidence in cardiovascular (CV) 
outcomes of Atorvastatin calcium 2. 
Literature review revealed that there are various 
methods for determination of Atorvastatin 
calcium, individually and in combination with 
other drugs. A variety of analytical methods are 
reported such as, estimation of enantiomeric of 
Atorvastatin 3, in human serum 4 and its impurity 
in bulk drugs 5. The majority of methods 
reported are liquid chromatography in which 
atorvastatin was estimated simultaneously with 
ezetimibe 1, 6, 7, fenofibrate 8, aspirin 9, 10, 
ramipril 11, 12, nicotinic acid 13 and amlodipine 14, 
15, 16, 17, 18. Some stability indicating RP-HPLC 
methods of atorvastatin and amlodipine 19 was 
also reported. Some triple combination of 
atorvastatin was reported with aspirin and 
pioglitazone 20.  
The present manuscript describes a simple, 
rapid, precise and accurate isocratic 
Reversed‐phase HPLC method for determination 
of Atorvastatin calcium in the tablet dosage 
forms 2. 
 
2. Experimental: 
a. Chemicals: Atorvastatin (101.5%) was 
obtained from Cipla Pharmaceutical Ltd, 
Mumbai, India, as gift samples. Acetonitrile 
(HPLC Grade), Methanol (HPLC Grade), 
Potassium dihydrogen phosphate (AR Grade), 
ortho‐phosphoric acid (AR Grade) were 
purchased from E. Merck (India) Ltd. The 
0.45‐µm nylon filters were purchased from 
Advanced Micro Devices Pvt. Ltd. Chandigarh, 
India. Mili‐Q water was used throughout the 
experiment. Tablets were purchased from Indian 
market containing of Atorvastatin 10 mg per 
tablet. 
b. Instruments: Analysis was performed on a 
chromatographic system Agilent 1200 series 
separation module (Japan) equipped with an 
auto injector (G1329A), Diode array detector SL 
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(G1315C), Quaternary pump (G1311A) and 
column thermostat (G1316A). Data acquisition 
was made with Chemstation software. The peak 
purity was evaluated with DAD detector. 
c. Liquid chromatographic conditions: 
Chromatographic conditions were obtained 
using a stainless steel column (Waters symmetry 
C18 250mm x 4.6mm 5µm), which was 
maintained at 40⁰C. The analytical wavelength 
was set at 246 nm and samples of 20µl were 
injected to HPLC system. The mobile phase was 
Potassium dihydrogen phosphate (10mM, pH 
3.0 adjusted with ortho‐phosphoric acid) and 
acetonitrile in ratio of 60:40 (v/v) at a flow rate 
of 1ml/min. The mobile phase was filtered 
through 0.45µm filter and degassed for 10 
minutes by sonication. 
d. Standard solutions:  
• Stock standard solutions:  An accurately 
weighed quantity of 10 mg of Atorvastatin 
calcium was transferred into a 100 ml 
volumetric flask. Dissolved with 25 ml of 
methanol and diluted to required volume 
with mobile phase, having the concentration 
of 100 µg/ml of Atorvastatin calcium.  
• Preparation of working standard: From 
the standard stock solution 10 ml is pipette 
out into 100 ml volumetric flask and made 
up the volume with mobile phase, having the 
concentration of 10 µg/ml of Atorvastatin 
calcium. 
• Preparation of laboratory mixture: 
Accurately weighed quantities of ATOR 
(≈10 mg) was transferred into a 100 ml 
volumetric flask, than dissolved with 25 ml 
of methanol and diluted to required volume 
with mobile phase, having the concentration 
of 100 µg/ml of ATOR. An accurately 
measured 1.0 ml portion of the resultant 
solution was diluted to 10.0 ml with diluent 
to obtain a laboratory mixture having 
concentration similar to marketed 
formulation. 
• Sample preparation:  Twenty tablets 
(ATOCOR, Dr. Reddy’s) were weighed and 
ground to a fine powder. An amount of 
powder equivalent to 10mg of Atorvastatin 
calcium was weighed accurately and 
transferred into a 100 ml A‐grade volumetric 
flask containing 25 ml of methanol and 
sonicated for 30 min to effect complete 
dissolution of the Atorvastatin and diluted 
upto 100 ml with diluent, then the solution 
was filtered through 0.45 µm membrane 
filter and 10 ml of filtrate taken into 100 ml 
volumetric flask. The aliquot portion of the 
filtrate was further diluted to get final 
concentration of 10 µg/ml of Atorvastatin 
calcium. 
e. Linearity study and Calibration curve: To 
study the linearity range of component, serial 
dilutions were made to obtain working standards 
in the concentration range of Atorvastatin 
calcium (5-25 µg/ml). A graph was plotted as 
concentration of drugs versus peak area response 
and results found linear for analytes. From the 
standard stock solution, a mixed standard of 
working concentration was prepared containing 
Atorvastatin calcium (10 µg/ml). The system 
suitability test was performed from five replicate 
injection of mixed standard solution. 
f. Analysis of Laboratory Mixture: In order to 
establish suitability of the proposed method for 
quantative estimation of Atorvastatin calcium in 
the pharmaceutical formulations, the method 
was first tried for the estimation of the 
component in a standard laboratory mixture of 
two drugs by using eq. 1and 2.  
g. Analysis of Marketed Formulation: 20 µl of 
the standard and sample are injected separately 
and chromatograms are generated. With peak 
area obtained for standard and sample, the 
content of ATOR in each tablet was calculated 
using the following equation: 
Amount of drug present in each tablet = 
 
Sample area x Std. Conc. x Std. Purity x Avg. weight 
                                               
              Std. area x Sample conc.         …………. (1)                           
  
                                   Amount present 
Percentage label claim =                             x  100 
                                                 Label claim   
                                              …..………… (2) 
 
h. Recovery study:  Recovery studies were 
performed to validate the accuracy of developed 
method. For recovery study different 
concentrations (50%, 100% and 150%) of 
standard drug was prepared and then its recovery 
was analyzed. 
 i. Method validation: The HPLC method was 
validated in terms of precision, accuracy, 
specificity and linearity according to ICH 
guidelines 22.  
Accuracy: The accuracy of the assay method 
was evaluated with the recovery of the standards 
from excipients. Three different quantities (low, 
medium and high i.e. 50%, 100% and 150%) of 
the authentic standards were added to the 
placebo. The mixtures were extracted as 
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described in section 2d, and were analyzed using 
the developed HPLC method. 
Precision: Assay method precision was 
determined using nine‐independent test solutions 
(3 concentration/3 replicates). To study 
precision 80%, 100% and 120% concentration 
was prepared and three replicate of each 
concentration was injected. The intermediate 
precision of the assay method was also evaluated 
using different analyst different days. 
Specificity: Accurately weighed quantities of 
the tablets powder equivalent to about 10 mg of 
ATOR was taken in a dry 50.0 ml volumetric 
flask. Each sample solution was stored under 
following different relevant small stress 
conditions (light, heat, acid/base hydrolysis and 
oxidation) for sufficient time (24 hrs) to achieve 
10 to 30% degradation of the initial sample. 
1. Addition of small amount of alkali 
solution (0.1 N NaOH).  
2. Addition of small amount of acid 
solution (0.1 N HCl). 
3. Addition of small amount of oxidative 
agent (3% H2O2). 
4. Sample solution was heated 50 0C on 
water bath for a sufficient time 
5. Sample solution was exposed 600 foot-
candle of UV light for a sufficient time. 
 
After 24 hr each treated sample was analyzed 
and percent labeled claims were calculated by 
the method using formula under estimation of 
ATOR by proposed method. 
Linearity: Solutions for linearity study were 
prepared as described in Section 2e. Six 
replicates of each concentration were injected 
and results are examined and it was found that 
calibration curve was linear in the concentration 
range of 5-25 µg/ml for TELM with correlation 
coefficient (R2) 0.999.  
LOD and LOQ:  The LOD and LOQ for 
analytes were estimated by SD of injecting a 
series of dilute solutions of known 
concentrations.  
Ruggedness: Ruggedness was ascertained by 
getting the sample analyzed from different 
analysts and carrying out analysis on different 
days by proposed method. 
Robustness: To determine the robustness of the 
method, the final experimental conditions were 
altered and the results were examined. The ratio 
of mobile phase was varied. 
 
3. Results and Discussion: 
Optimization of the chromatographic 
conditions: In order to develop RP‐HPLC 
method for antihyperlipidemic drug Atorvastatin 
in formulation. The chromatographic conditions 
were optimized for better resolution by using 
different buffers like phosphate, acetate and 
citrate for mobile phase preparation. After a 
series of screening experiments, it was 
concluded that Phosphate buffer (10mM 
Phosphate buffer pH at 3.0) gave better peak 
shapes than their acetate and citrate counterparts. 
With methanol as solvent both the peaks shows 
less theoretical plates and bad peak shapes, on 
changing to acetonitrile the peak shape 
improved along with theoretical plates. Further 
optimization experiments were carried out 30% 
and 40% of acetonitrile in mobile phase. The 
best peak shape and maximum separation was 
achieved with mobile phase composition 
consisting acetate buffer‐acetonitrile (60:40 v/v). 
The best separation, peak symmetry and 
reproducibility were obtained on Waters 
symmetry C18, 250 mm x 4.6 mm, 5 µm column 
compared to Hypersil ODS C18, 250 mm x 4.6 
mm, 5 µm. The optimum wavelength for 
detecting the analytes was ascertained and found 
to be 246 nm.  
The specificity of the HPLC method is 
illustrated in Fig. 2 and Fig. 3, where complete 
separation of Atorvastatin was noticed in 
presence of tablet excipients and its impurities 
produced by alkali and thermal degradation. 
There were no interfering peaks of endogenous 
compounds observed at the retention time of the 
analytes.  
Accuracy of the method was calculated by 
recovery studies at three levels by standard 
addition method (Table 1). The mean percentage 
recoveries obtained for Atorvastatin were 
100.23. 
Precision is the degree of repeatability of an 
analytical method under normal operational 
conditions. The system precision is a measure of 
the method variability that can be expected for a 
given analyst performing the analysis and was 
determined by performing 80%, 100% and 
120% analyses of the working solution.  
The intra‐day, inter‐day, analyst and instruments 
variability or precision data are summarized in 
Table 3.  The R.S.D of the assay results, 
expressed as percentage of the label claim, was 
used to evaluate the method precision. The 
inter‐day precision was also determined by 
assaying the tablets in triplicate per day. The 
results indicated the good precision of the 
developed method. 
The developed method was applied to the 
analysis of Atorvastatin in tablet dosage from 
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marketed as ATOCOR (Label claim 10 mg 
strength, Dr. Reddy’s). The results of analysis 
are given in Table 5 and fig. 4. The contents of 
marketed tablet dosage form were found to be in 
the range of 100±2% with RSD less than 2% 
which indicate suitability for routine analysis of 
Atorvastatin in tablet dosage form. 
The robustness of an analytical procedure is a 
measure of its capacity to remain unaffected by 
small, but deliberate variations in method 
parameters and provides an indication of its 
reliability during normal usage. Robustness of 
the method was investigated under a variety of 
conditions including changes of pH of the 
mobile phase, flow rate, percentage of 
acetonitrile in the mobile phase. The mixed 
standard solution is injected in five replicates 
and sample solution of 100% concentration is 
prepared and injected in triplicate for every 
condition and % R.S.D. of assay was calculated 
for each condition. The degree of reproducibility 
of the results obtained as a result of small 
deliberate variations in the method parameters 
has proven that the method is robust (Table 4). 
 
Conclusion: 
A simple, specific, linear, precise and accurate 
RP‐HPLC method has been developed and 
validated for quantitative determination of 
Atorvastatin tablet formulation. The method is 
very simple and specific as both peaks are well 
separated from its excipient peaks and with total 
runtime of 12 min, makes the developed method 
it’s suitable for routine quality control analysis 
work. 
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Figures :  
 
 
Fig. 1 Structure of Atorvastatin 
 
Fig. 2 Alkali degradation test solution for specificity 
 
 
Fig. 3 Thermal degradation test solution for specificity 
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Fig. 4 Test solution for assay 
 
Table 1 Results of recovery analysis of Atorvastatin 
Compound Wt. Spiked (%) Wt. recovered (%) Recovery (%) RSD (%) n=3 
Atorvastatin 50 50.60 101.2 0.008
100 99.733 99.73 0.005 
150 149.663 99.77 0.004 
 
Table 2 System suitability Parameter of Atorvastatin 
Parameters Atorvastatin 
Theoretical plates 7425 
Peak Height 5.57 
Peak Symmetry 0.935 
USP tailing 1.026 
Width at half height 0.640 
 
Table 3 Results of precision of Atorvastatin 
Compound Precision Mean RSD (%) 
Atorvastatin Intra day 99.62 0.042 
Inter day 99.64 0.014 
Analyst 99.64 0.014 
Instrument 99.65 0.007 
 
Table 4 Results of robustness study of Atorvastatin 
Factor Level Mean % assay (n=3) RSD (%)
pH of mobile phase 3 99.6 0.209 
3.2 99.1 0.308 
Flow rate (ml/min) 1 99.5 0.058 
1.3 99.2 0.153 
% of Acetonitrile 30 99.2 0.209 
40 100.8 0.210 
 
Table 5 Quantitative analysis of marketed formulation of Atorvastatin  
Tablet 
Sample 
Label Claim (mg) Amount present 
(mg/tablet) 
%Label Claim %Deviation 
Ator 10 10.15 100.99 +0.99 
 
 
